CytoMed Therapeutics Refutes Misleading Claims and Reaffirms Clinical Progress
Rhea-AI Summary
CytoMed Therapeutics (NASDAQ: GDTC) issued a statement on January 28, 2026, rejecting inaccurate public claims about its research, clinical progress, and operations. The company confirmed its lead CAR γδ T cell program received regulatory approval for a first-in-human trial, currently ongoing at National University Hospital, Singapore.
CytoMed said other candidates, including iPSC-derived γδ NKT therapies, remain in preclinical development and that no product is approved for commercial use.
Positive
- Lead CAR γδ T cell program received regulatory approval to proceed
- First-in-human CAR γδ T cell trial ongoing at National University Hospital (Singapore)
- iPSC-derived γδ NKT cell candidates actively maintained in preclinical development
Negative
- No therapeutic candidate approved for commercial use or clinically validated beyond stage
- Publicly circulated mischaracterizations risk affecting GDTC share price
News Market Reaction
On the day this news was published, GDTC declined 1.29%, reflecting a mild negative market reaction. Argus tracked a peak move of +12.5% during that session. Argus tracked a trough of -2.3% from its starting point during tracking. Our momentum scanner triggered 4 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $135K from the company's valuation, bringing the market cap to $10M at that time.
Data tracked by StockTitan Argus on the day of publication.
Market Reality Check
Peers on Argus
GDTC fell 6.1% while momentum peers were mixed: QTTB down 6.27%, but LIXT and NRXS appeared in scanners with gains of 4.02% and 4.60%. Broader biotech peers in the affinity list also showed both up and down moves, pointing to stock-specific pressure rather than a uniform sector rotation.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 13 | Pipeline and strategy update | Positive | -1.6% | Outlined 2026 clinical plans, funding runway, and shareholder engagement initiatives. |
| Dec 08 | Clinical trial collaboration | Positive | +4.5% | MoU for multi-site Phase I trial of donor-derived gamma delta T cells in Malaysia. |
| Nov 06 | Non-dilutive investment | Positive | -3.3% | Non-dilutive LongevityBank funding and new China strategy focused on cell therapies. |
| Oct 22 | Insider share purchase | Positive | +4.3% | Executive Chairman increased effective holdings to 21.95% through open-market buys. |
| Oct 14 | Asset acquisition bid | Positive | +16.6% | Cash bid for TC BioPharm assets to deepen gamma delta T cell capabilities. |
Positive operational or strategic updates have often met mixed price reactions, with several upbeat announcements followed by either modest gains or declines.
Over the last few months, CytoMed reported multiple developments: a cash bid for TC BioPharm assets on Oct 14, 2025 (price move +16.58%), the chairman’s stake increase to 21.95% on Oct 22, 2025 (+4.28%), and a non-dilutive LongevityBank investment on Nov 6, 2025 (-3.32%). A Malaysia Phase I trial MoU on Dec 8, 2025 saw a +4.52% move, while the Jan 13, 2026 clinical and corporate update coincided with a -1.61% decline. The current clarification statement fits into this ongoing effort to assert clinical progress and governance.
Market Pulse Summary
This announcement directly addresses publicly circulating claims about CytoMed’s research programs, clinical progress, and regulatory status, reiterating that its CAR γδ T cell program has first‑in‑human approval in Singapore while other candidates remain preclinical. Recent history includes an acquisition bid, a non‑dilutive investment, and a new year pipeline update, showing active strategic repositioning. Investors monitoring this situation may focus on future official disclosures, progress in the ongoing trial at National University Hospital, and any follow‑up actions the company takes regarding misinformation.
Key Terms
car γδ t cell therapies medical
ipsc-derived γδ nkt cell therapies medical
first-in-human (fih) clinical trial medical
immunotherapies medical
AI-generated analysis. Not financial advice.
SINGAPORE, Jan. 28, 2026 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or the “Company”), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary technologies to develop novel affordable donor-derived cell-based immunotherapies for the treatment of a broad range of cancers, including both blood and solid tumors, today issued a statement to address recent statements containing inaccurate and misleading claims regarding the Company’s research programs, clinical progress, and operations.
CytoMed categorically rejects such claims which have no basis. Certain statements circulating publicly mis-characterize the Company’s scientific focus, development status, and regulatory standing. Please refer to recent announcements by the Company on our progress.
CytoMed’s research is focused on CAR γδ T cell therapies and iPSC-derived γδ NKT cell therapies, based on established immunological science. The Company’s lead CAR γδ T cell program has received regulatory approval to proceed with a first-in-human (FIH) clinical trial, which is currently ongoing at National University Hospital (NUH), Singapore. This clinical activity is conducted in accordance with applicable regulatory and ethical requirements.
Other programs, including iPSC-derived γδ NKT cell candidates, remain in preclinical development. CytoMed does not claim that any of its therapeutic candidates are approved for commercial use or clinically validated beyond their current stage of development.
Assertions regarding CytoMed’s regulatory status, manufacturing capabilities, governance, or financial transparency that contradict the above facts are inaccurate or taken out of context and designed to affect the Company’s share price. The Company operates in compliance with applicable regulations and follows development practices appropriate for its stage.
CytoMed remains committed to advancing its pipeline responsibly and to communicating accurate, timely information through official Company disclosures. The Company reserves the right to take appropriate action to address the dissemination of false or misleading information that may adversely affect its reputation or stakeholders.
Shareholders can contact the below person for clarification.
About CytoMed Therapeutics Limited (CytoMed)
Incorporated in 2018, CytoMed was spun off from the Agency for Science, Technology and Research (A*STAR), Singapore’s leading research and development agency in the public sector. CytoMed is a clinical stage biopharmaceutical company focused on harnessing its licensed proprietary technologies, namely gamma delta T cell and iPSC-derived gamma delta Natural Killer T cell, to create novel cell-based allogeneic immunotherapies for the treatment of various human cancers. The development of novel technologies has been inspired by the clinical success of existing CAR-T therapies in treating haematological malignancies, as well as the current clinical limitations and commercial challenges in extrapolating the CAR-T principle into the treatment of solid tumours. For more information, please visit www.cytomed.sg and follow us on Twitter (“X”) @CytomedSG, on LinkedIn, and Facebook.
Forward-Looking Statements
This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as “may, “will, “intend,” “should,” “believe,” “expect,” “anticipate,” “project,” “estimate” or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company’s expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the following: the Company’s plans to develop and commercialize its product candidates; the initiation, timing, progress and results of the Company’s current and future pre-clinical studies and clinical trials and the Company’s R&D programs; the Company’s estimates regarding expenses, future revenue, capital requirements and needs for additional financing; the Company’s ability to successfully acquire or obtain licenses for additional product candidates on reasonable terms; the Company’s ability to establish and maintain collaborations and/or obtain additional funding and assumptions underlying or related to any of the foregoing and other risks contained in reports filed by the Company with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company’s filings with the SEC, which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward–looking statements to reflect events or circumstances that arise after the date hereof.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.
Contact:
CytoMed Therapeutics Limited
enquiry@cytomed.sg
Attention: Evelyn Tan, Chief Corporate Officer
FAQ
Has CytoMed (GDTC) started a first-in-human CAR γδ T cell trial?
Are any CytoMed (GDTC) therapies approved for commercial use?
What is CytoMed's (GDTC) lead research focus and pipeline status as of Jan 28, 2026?
Does CytoMed (GDTC) dispute claims about its regulatory or manufacturing status?
How should investors verify CytoMed (GDTC) clinical progress and disclosures?
